AI-First Pharmatech Company, a game-changer in AI-driven drug developing process. We discover, design and develop the drug by sequence-based end-to-end AI solution. - By integrating advanced AI technology and experts experience, Deargen is committed to discovering, designing and developing the best possible drugs in the fastest and most effective way. - Deargen specializes in discovering the Hit/Lead compound regardless of the target protein’s 3D information by first applying transformer technology into the pharmaceutical field. - Deargen members are experts in drug development, deep learning, software, biology, computational & medicinal chemistry, etc., for target discovery to lead optimization. Our end-to-end solution of AI platform allows saving time and cost compared to the traditional methods of drug discovery and development. - Deargen assures you that we can meet your unmet scientific needs by providing technology and experiences to develop new drugs.
| Website | https://deargen.me/ |
| Employees | 12 (12 on RocketReach) |
| Founded | 2016 |
| Phone | +82 42-716-2100 |
| Technologies |
HTML
,
Twitter
,
Google Analytics
+5 more
(view full list)
|
| Industry | IT Services and IT Consulting, Discovery Tools (Healthcare), Drug Discovery |
| Keywords | Ai Drug Discovery, Computational Drug Design, Drug Development Ai, Data Driven Drug Discovery, Biotechnology Ai, Innovative Drug Discovery, Ai In Pharma, Precision Medicine Ai, Pharmaceutical Technology |
| Competitors | Recursion Pharmaceuticals, Insilico Medicine, EQS Group, XtalPi Inc., Atomwise, BenevolentAI, GENOOX, NuMedii, Synthex, Celeris Corporation +30 more (view full list) |
Looking for a particular Deargen employee's phone or email?
Gilsu Kang is the CEO of Deargen.
12 people are employed at Deargen.